KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia
These results demonstrate the independent prognostic value of KRAS mutations across treatment modalities, including both conventional chemotherapy and hematopoietic stem cell transplantation.
Authors
- Xiaoyu Lai (ORCID: https://orcid.org/0000-0002-3093-8476)
- Jimin Shi (ORCID: https://orcid.org/0000-0002-1852-326X)
- Weiyan Zheng
- Yibo Wu (ORCID: https://orcid.org/0000-0002-5431-1133)
- Yi Luo (ORCID: https://orcid.org/0000-0001-7051-219X)
- Wenjun Wu (ORCID: https://orcid.org/0000-0002-2528-4893)
- Panpan Zhu (ORCID: https://orcid.org/0000-0002-3348-7674)
- Zhen Cai (ORCID: https://orcid.org/0000-0001-6026-3804)
- He Huang (ORCID: https://orcid.org/0000-0002-2723-1621)
- Yuanyuan Zhu
- Yue Liang
- Jian Yu (ORCID: https://orcid.org/0000-0002-8704-1571)
- Xiaolin Yuan
- Jie Sun (ORCID: https://orcid.org/0000-0001-7835-3656)
- Luxin Yang
- Yanmin Zhao
- Shanshan Pei
- Lizhen Liu
Institutions
- Chinese Academy of Sciences (CN)
- Zhejiang Cancer Hospital (CN)
- Cell Technology (China) (HK)
- Hangzhou Cancer Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1002/cncr.35941
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- National Natural Science Foundation of China